Summary: In central nervous system drug discovery, cerebrospinal fluid (CSF) drug concentration (C CSF ) has been widely used as a surrogate for unbound brain concentrations (C u,brain ). However, previous rodent studies demonstrated that when drugs undergo active efflux by transporters, such as P-glycoprotein (P-gp), at the blood-brain barrier, the C CSF overestimates the corresponding C u,brain . To investigate the utility of C CSF as a surrogate for interstitial fluid (ISF) concentration (C ISF ) in nonhuman primates, this study simultaneously determined the C CSF and C ISF of 12 compounds, including P-gp substrates, under steady-state conditions in cynomolgus monkeys using intracerebral microdialysis coupled with cisternal CSF sampling. Unbound plasma concentrations of non-or weak P-gp substrates were within 2.2-fold of the C ISF or C CSF , whereas typical P-gp substrates (risperidone, verapamil, desloratadine, and quinidine) showed ISF-to-plasma unbound (K p,uu,ISF ) and CSF-to-plasma unbound concentration ratios (K p,uu,CSF ) that were appreciably lower than unity. Although the K p,uu,CSF of quinidine, verapamil, and desloratadine showed a trend of overestimating the K p,uu,ISF , K p,uu,CSF showed a good agreement with K p,uu,ISF within 3-fold variations for all compounds examined. C u,brain of some basic compounds, as determined using brain homogenates, overestimated the C ISF and C CSF . Therefore, C CSF could be used as a surrogate for C ISF in nonhuman primates.
Introduction
In drug discovery, the plasma concentration of unbound drugs (C u,plasma ) has been used to elucidate the correlation between pharmacokinetics and pharmacodynamics on the basis of the "free drug hypothesis". 1) However, differences between the C u,plasma and the unbound brain concentration (C u,brain ) have been observed, mainly due to the restrictive role of the blood-brain barrier (BBB), which has highly developed tight junctions between adjacent endothelial cells and active efflux transporters, such as P-glycoprotein (P-gp/ABCB1), 2) breast cancer resistance protein (BCRP/ABCG2), 3, 4) and multidrug resistance-associated protein 4 (MRP4/ABCC4), 5, 6) limiting drug penetration of the central nervous system (CNS). As only unbound drugs in the brain interstitial fluid (ISF) are available to interact with their targets in the CNS, a comparison of drug ISF concentrations (C ISF ) with the pharmacologically effective concentration estimated from in vitro pharmacological studies is crucial to quantitatively assess the mechanisms of action. Moreover, poor CNS exposure requires higher doses of a drug candidate to elicit an efficacious response in the CNS, resulting in higher drug exposure and a narrower therapeutic index against peripheral toxicity. Therefore, lead optimization with an appropriate approach to estimate C ISF of drug candidates is indispensable to CNS drug discovery.
Several approaches have been utilized to measure or estimate C ISF , and microdialysis is the only method that can directly access brain ISF, in which the microdialysis probe is implanted in the brain to supply and collect the perfusate in equilibrium with drugs in the ISF. 7, 8) Due to technical challenges and the low throughput, it is difficult to routinely implement microdialysis in drug discovery. Instead, cerebrospinal fluid (CSF) drug concentration (C CSF ) has been widely used as a surrogate for C ISF on the assumption of rapid equilibrium between the ISF and CSF compartments. [9] [10] [11] [12] However, as expected from the complexity of the CSF anatomy and physiology, there have been cases where the C CSF deviated from the C ISF ; 13) hence, it is important to consider the applicability and limitations of C CSF as a surrogate for C ISF for successful CNS drug discovery. Several reports have demonstrated that the C CSF -to-C ISF gradient is evident for substrates of the active efflux transporters P-gp and/ or BCRP in rodents. [14] [15] [16] [17] They are expressed not only at the BBB, but also in the choroid plexus epithelial cells constituting the blood-CSF barrier (BCSFB), where P-gp is reportedly localized to the cytoplasm or subapical membrane 18) and BCRP to the brush border membrane, 15) suggesting that they do not limit drug penetration into the CSF at the BCSFB. In addition, knockout of P-gp and/or BCRP diminished the gradient. 17) These findings support the supposition that CNS-to-blood directed active efflux by P-gp and/or BCRP is dominant at the BBB over the BCSFB and is a determinant of the C CSF -to-C ISF gradient in the brain. However, these findings have been reported in rodents; therefore, the impact of active efflux on the gradient remains to be elucidated in nonhuman primates and humans.
Since nonhuman primates are considered to be well suited to investigate pharmacological targets in the CNS due to the high genetic similarity to humans, a detailed understanding of the CNS drug distribution contributes to CNS drug discovery. Although drug CNS distribution has been investigated in nonhuman primates using invasive or noninvasive methods, [19] [20] [21] [22] little direct comparison of C ISF and C CSF has been carried out, particularly for P-gp substrates. The brain distribution of positron emission tomography radioligands and quantification of P-gp protein expression suggest the presence of interspecies differences in active efflux at the BBB between rodents and nonhuman primates or humans, [22] [23] [24] [25] which also warrants further investigation in nonhuman primates.
Therefore, this study simultaneously determined and compared the C ISF , C CSF , and C u,plasma of 12 compounds, including P-gp substrates, under steady-state conditions using intracerebral microdialysis coupled with cisternal CSF sampling in cynomolgus monkeys. Moreover, unbound drug concentrations in brain tissues were determined by the brain homogenate method and compared with C ISF and C CSF .
Materials and Methods
Chemicals: Antipyrine, carbamazepine, lucifer yellow CH dilithium salt, metoclopramide hydrochloride, ondansetron hydrochloride dihydrate, propranolol hydrochloride, quinidine hydrochloride, and verapamil hydrochloride were purchased from Sigma Aldrich (St. Louis, MO). Midazolam, desloratadine, and risperidone were purchased from Wako Pure Chemical Industries (Osaka, Japan), LKT Laboratories (St Paul, MN), and AK Scientific (Union City, CA), respectively. A proprietary compound, E2074, synthesized in Tsukuba Research Laboratories, Eisai (Ibaraki, Japan) was used. 26) All other reagents and solvents were of analytical grade and commercially available.
Animals: All experimental protocols and procedures were approved by the Institutional Animal Care and Use Committee of Trans Genic (Kumamoto, Japan) and Eisai. Eight male cynomolgus monkeys (4-7 years old, 3.6-5.1 kg) supplied by Trans Genic were used for in vivo microdialysis studies. All surgeries and procedures were performed by veterinarians in Trans Genic, and animal condition before, during, and after surgery was closely monitored by the veterinarians. All efforts were made to minimize suffering.
Intracerebral microdialysis with CSF and blood sampling: One to 2 weeks before the initial dosing, animals were pretreated with an analgesic (meloxicam, 0.3 mg/kg, s.c.), and a heparincoated polyurethane catheter (Solomon Scientific, San Antonio, TX) was surgically placed into the cisterna magna under ketamine (10 mg/kg, i.m.) and pentobarbital anesthesia (30 mg/kg, i.v.). Cefamezin (100 mg/body, i.v.) was administered once daily for three days post-operatively. Thereafter, under anesthesia, 1-mm burr holes were created at approximately 10 mm from the midline in the right and left anterior parietal bones, and a small dural incision was made. A CG-8 guide cannula (Eicom, Kyoto, Japan) with AD-8 dummy cannula (Eicom) was implanted in the cerebral cortex and fixed to the skull, and the surgical site was treated with cefamezin solution. On the day of dosing, a C-I-8 microdialysis probe (Eicom) with a 5-mm regenerated cellulose membrane (50-kDa molecular weight cut off) was inserted into the guide cannula under the anesthesia, so that the probe membrane tip was placed at 10 mm from the brain surface. A second microdialysis probe was also implanted in the contralateral side in the same manner for retrodialysis. After full recovery of the animals from the anesthesia and completion of retrodialysis study, the microdialysis probe was perfused with Ringer HEPES buffer (RHB) (147 mM NaCl, 4.7 mM KCl, 0.6 mM MgSO 4 07H 2 O, 2.5 mM CaCl 2 02H 2 O, 5 mM HEPES, pH 7.4) at a flow rate of 1.5 µL/min using a syringe pump (Harvard Apparatus, Holliston, MA). One to 2 h after the preperfusion, a cocktail of two or three compounds was infused via the cephalic vein following an intravenous bolus dose for antipyrine (infusion rate, 0.10 mg/h/kg; bolus dose, 0.23 mg/kg), carbamazepine (0.10; 0. . Although diphenhydramine and ketotifen were also evaluated, the results will be reported separately for other purposes. In the present study, cassette dosing was adopted to minimize the study period and the number of animals used. Since some compounds used in this study are reported to be P-gp inhibitors (e.g., verapamil and quinidine), the dose levels were optimized so that the C u,plasma was kept equal to or less than lower limit of reported half maximal inhibitory concentrations for P-gp 27) based on a previous report.
28)
The microdialysis dialysate was serially collected at 30-minute intervals up to 4 h postdose. Blood (0.5 mL per sampling point) and CSF (0.25 mL per sampling point) were also serially collected at 1-h intervals up to 4 h postdose via the saphenous vein and cisterna magna, respectively, and the blood samples were centrifuged to prepare plasma. The animals received a cocktail of two or three compounds on a once-weekly basis. Brain tissue sampling: At least a one-week washout period was introduced after the microdialysis experimental phase. Then, each animal received a cocktail of two or three compounds (monkey-1, antipyrine, midazolam, and quinidine; monkey-2, carbamazepine, diphenhydramine, and verapamil; monkey-3, metoclopramide, ketotifen, and ondansetron; monkey-4, desloratadine, E2074, and risperidone; monkey-5, lamotrigine and propranolol) by intravenous infusion following an intravenous bolus dose as described above. At 4 h after infusion, the animals were euthanized by exsanguination under anesthesia, and the blood and brain tissues were collected. The brain tissues were sampled from six different regions of the cerebral cortex to confirm no regional difference in drug concentration within the cerebral cortex. The blood samples were centrifuged to prepare plasma. The brain tissues were homogenized with distilled water to prepare 20% homogenates (w/v) before analysis.
Microdialysis probe recovery: The microdialysis probe recovery was determined as described earlier. 29) In vitro recovery gain (RG vitro ) and loss (RL vitro ), and in vivo recovery loss (RL vivo ) values were obtained as described in Supplemental Table 1 . On the basis of the probe recovery, concentration of a test compound in ISF (C ISF ) was calculated from the dialysate concentration (C dialysate ) as follows:
Unbound fractions in brain, plasma, and CSF: The in vitro unbound fractions of each compound in monkey brain (f u,brain ), plasma (f u,plasma ), and CSF (f u,CSF ) were determined using an equilibrium dialysis apparatus, HTD 96b (HTDialysis, Gales Ferry, CT). Details of the protein binding assay procedure are given in Table 2 . f u,plasma and f u,CSF were calculated as the receiver side to donor side concentration ratio. f u,brain was calculated as follows: 14) f u,brain ¼ 1=D
where, D and f u A represent a dilution factor (5-fold) to prepare 20% brain homogenates and unbound fraction determined in the 20% brain homogenate, respectively. Transcellular transport via human P-gp-expressing cell and control cell monolayers: Human P-gp-expressing LLC-PK1 cells (LLC-PK1 cells transfected with human P-gp/ABCB1 cDNA) and the corresponding control LLC-PK1 cells that were obtained from the Netherlands Cancer Institute (Amsterdam, Netherlands) and maintained in Medium199 (Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum, penicillin (final concentration, 50 units/mL), and streptomycin (50 µg/mL) were used for transcellular transport studies. The assay procedures are given in Table 1 .
Analytical procedure: Samples from the microdialysis probe recovery assay, protein binding assay, in vivo studies, and P-gp transcellular transport assay were mixed with acetonitrile containing an appropriate internal standard followed by centrifugation. The resulting supernatant was filtered, and an aliquot of the filtrate was subjected to high-performance liquid chromatography with tandem mass spectrometry analysis. Details of the analytical conditions are given in Supplemental Table 2 .
Calculations: The brain-to-plasma drug concentration ratio (K p,brain ) was obtained by dividing brain total concentration (C brain ) by plasma total concentration (C plasma ). The plasma unbound concentration (C u,plasma ) was a product of C plamsa and f u,plasma . The brain unbound concentration determined by brain homogenate method (C u,b,homogenate ) was obtained from a product of C brain and f u,brain . The ISF-to-plasma unbound concentration ratio (K p,uu,ISF ), CSF-toplasma unbound concentration ratio (K p,uu,CSF ), and ratio of brain unbound concentration determined by the brain homogenate method to plasma unbound concentration (K p,uu,brain ) were calculated as follows:
K p,uu,CSF/ISF was defined as follows:
Western blot analysis: Western blot analysis was conducted for the cerebral cortex, choroid plexus, and brain capillary-enriched fraction prepared from male cynomolgus monkeys to investigate the protein expression of P-gp at the BBB and BCSFB according to a previous report. 30) Details of the study procedure are given in Supplemental Figure 1 .
Results
In vitro membrane permeability and P-gp susceptibility:
The membrane permeability and P-gp susceptibility of the 12 compounds selected were characterized using human P-gp-expressing LLC-PK1 cells and control LLC-PK1 cells ( Table 1 ). The compound with a corrected efflux ratio (CER) of equal to or greater than 2 was defined as a P-gp substrate, based on regulatory drug interaction draft guidance materials and guidelines. 31, 32) In addition, the compound with 2¯CER < 3 was classified as a weak P-gp substrate, and that with 3¯CER was as a good P-gp substrate in this study. P app values of the test compounds ranged from 9.67 © 10 ¹6 (desloratadine) to 23.5 © 10 ¹6 cm/s (midazolam), which were at least 7.9-fold higher than that of Lucifer yellow, a paracellular marker (1.22 © 10 ¹6 cm/s). Transcellular transport studies revealed that these 12 compounds included non-P-gp substrates (antipyrine, carbamazepine, lamotrigine, midazolam, and propranolol) (CER, 1.0-1.1), and weak (ondansetron, metoclopramide, and E2074) (CER, 2.0-2.2) to good P-gp substrates (risperidone, verapamil, desloratadine, and quinidine) (CER, 3.9-13).
Unbound fractions in monkey plasma, brain, and CSF: f u,plasma , f u,brain , and f u,CSF values of the test compounds were determined by equilibrium dialysis in cynomolgus monkeys ( Table 2) . The f u,plasma and f u,brain values varied by 18.7-fold (0.0573 to 1.07) and 74.4-fold (0.0110 to 0.818), respectively. In contrast, the f u,CSF values showed minimal variation (1.22-fold) ranging from 0.827 to 1.01. As there was minimal impact of correction for f u,CSF on C CSF calculations, the observed C CSF without correction for f u,CSF was used for further analyses.
ISF, CSF, and brain distribution in cynomolgus monkeys: Time profiles of total and unbound plasma, CSF, and ISF concentrations of the 12 compounds after continuous intravenous infusion with bolus dosages are shown in Figure 1 . The C ISF of the test compounds was obtained from the C dialysate corrected for microdialysis probe recoveries (Supplemental Table 1 ). The compound concentrations in plasma, CSF, and ISF reached steady states within 3 or 4 h of infusion (Fig. 1) , and then the K p,uu,ISF and K p,uu,CSF values were determined ( Table 3) .
The K p,uu,ISF values of the 12 compounds ranged from 0.0609 to 1.27 ( Table 3) . Non-P-gp substrates (antipyrine, carbamazepine, midazolam, lamotrigine, and propranolol) showed K p,uu,ISF values of 0.472 to 1.27, where midazolam showed a K p,uu,ISF value of 0.472, which was significantly lower than unity. Among the weak P-gp substrates, ondansetron and E2074 exhibited K p,uu,ISF values of 0.483 and 0.480, respectively, which were significantly lower than unity, but that of metoclopramide approximated unity. The K p,uu,ISF values of typical P-gp substrates (risperidone, verapamil, desloratadine, and quinidine) were appreciably lower than unity, ranging from 0.0609 to 0.126.
The K p,uu,CSF values of the compounds ranged from 0.129 to 1.19 ( Table 3 ).
Brain and plasma concentrations of the 12 compounds were determined at 4 h postdose. The K p,brain and K p,uu,brain values ranged from 0.271 (quinidine) to 23.7 (propranolol), and 0.126 (quinidine) to 2.64 (E2074), respectively (Supplemental Table 3 ).
Correlations between in vitro P-gp-mediated transport activity and in vivo CNS distribution: The corrected efflux ratio (CER) values obtained from in vitro human P-gp-mediated transcellular transport studies ( Table 1) were plotted against the K p,uu,ISF ( Fig. 2A) , K p,uu,CSF (Fig. 2B) , and K p,uu,brain (Fig. 2C) values. Compounds with higher CERs (e.g., risperidone, verapamil, desloratadine, and quinidine) showed lower in vivo K p,uu,ISF and K p,uu,CSF values. A significant correlation was observed between CER and K p,uu,ISF or K p,uu,CSF values (p < 0.05), whereas the relationship between CER and K p,uu,brain did not reach statistical significance (p = 0.13).
Comparisons of K p,uu,ISF , K p,uu,CSF , and K p,uu,brain values: The K p,uu,ISF values of the test compounds were compared with the K p,uu,CSF (Fig. 3A) or K p,uu,brain (Fig. 3B) . The K p,uu values were considered similar when the compared two values were within 3-fold in this study according to previous studies. 9, 33) K p,uu,ISF showed a good agreement with K p,uu,CSF (R 2 = 0.802). The correlation between K p,uu,brain estimated by the brain homogenate method and K p,uu,ISF (R 2 = 0.245) (Fig. 3B) or K p,uu,CSF (R 2 = 0.119) (Fig. 3C ) was poor and did not reach statistical significance. The K p,uu,brain values of several basic compounds showed a tendency toward overestimating K p,uu,ISF and K p,uu,CSF , where the K p,uu,ISF values of deslotaradine, E2074, risperidone, propranolol, and ondansetron were overestimated by 14.5-, 6.4-, 5.4-, 3.0-, and 3.0-fold, and the K p,uu,CSF values of desloratadine, propranolol, risperidone, E2074, Unbound fractions of test compounds in cynomolgus monkey plasma (f u,plasma ), brain (f u,brain ), and CSF (f u,CSF ) were determined by equilibrium dialysis. Compound concentrations spiked into plasma were as follows: 0.1 µg/mL for carbamazepine, midazolam, verapamil, and E2074; 0.3 µg/mL for antipyrine, desloratadine, lamotrigine, metoclopramide, ondansetron, propranolol, and risperidone; 1 µg/mL for quinidine. Compound concentrations spiked into 20% brain homogenates were as follows: 0.3 µg/mL for antipyrine, carbamazepine, midazolam, quinidine, risperidone, verapamil, and E2074; 1 µg/mL for desloratadine, lamotrigine, metoclopramide, ondansetron, and propranolol. Compound concentrations spiked into CSF that was collected from the cisterna magna were as follows: 0.03 µg/mL for desloratadine, midazolam, propranolol, risperidone, verapamil, and E2074; 0.1 µg/mL for carbamazepine, lamotrigine, metoclopramide, ondansetron, and quinidine; 0.3 µg/mL for antipyrine. One hundred and fifty µL each of the matrices spiked with a test compound and phosphate buffered saline (pH 7.4) were added to the donor and receiver sides of the dialysis chamber, respectively, and the dialysis apparatus was incubated at 37°C for 24 h. Each value represents mean « SEM of three to six animals (for f u,plasma and f u,CSF ) or mean « SEM of three to six determinations in one animal (for f u,brain ).
a As f u,plasma of antipyrine was more than unity, f u,plasma = 1 was used for the calculation of C u,plasma . The ratio of P app in B-to-A direction to that in A-to-B direction in P-gp-expressing cells or the control LLC-PK1 cells. The ratio of ER in P-gp-expressing cells to that in the control LLC-PK1 cells. and ondansetron were overestimated by 6.8-, 6.2-, 5.1-, 4.2-, and 3.0-fold, respectively.
Protein expression of P-gp in the monkey cerebral cortex, choroid plexus, and brain capillary: In order to investigate the expression of P-gp at the BBB and BCSFB in nonhuman primates, Western blot analysis was conducted for the cerebral cortex, choroid plexus, and brain capillary-enriched fraction prepared from cynomolgus monkeys (Supplemental Fig. 1 ). P-gp was detected at 170 kDa not only in the capillary-enriched fraction, but also in the choroid plexus tissues, indicating that P-gp is expressed at both the BBB and BCSFB in cynomolgus monkeys.
Discussion
In order to investigate the utility of C CSF as a surrogate for C ISF in nonhuman primates, this study simultaneously determined the C ISF , C CSF , and C u,plasma of 12 compounds, including P-gp substrates, under steady-state conditions using intracerebral microdialysis coupled with cisternal CSF sampling in cynomolgus monkeys (Fig. 1) .
We confirmed that the K p,uu,ISF of most P-gp substrates, except for that of metoclopramide, were significantly lower than unity in cynomolgus monkeys (Table 3) . Moreover, the K p,uu,ISF decreased along with an increase in in vitro P-gp activities ( Fig. 2A) , suggesting that P-gp-mediated active efflux at the BBB is a determinant of K p,uu,ISF in nonhuman primates. Although in vitro P-gp transport activity of metoclopramide was similar to those of ondansetron and E2074 (Table 1) , the K p,uu,ISF of metoclopramide was approximately 2-fold higher than that of ondansetron and E2074, and approximated unity. In rodents, it is evident that metoclopramide undergoes P-gp-mediated active efflux at the , and quinidine (L) in cynomolgus monkeys after a constant intravenous infusion with an intravenous bolus dose are presented. Priming doses and infusion rates are given under Materials and Methods. Blood, CSF, and dialysate were serially collected from cynomolgus monkeys by intracerebral microdialysis in conjunction with a bloodand CSF-sampling method. ISF concentrations were obtained from dialysate concentrations corrected for microdialysis probe recoveries (Supplemental Table 1 ). Each point represents the mean « SEM of three to five animals or mean of two animals.
BBB. 11, 34) Since this study used human P-gp-expressing cells as in vitro systems, we cannot completely exclude the possibility of a great species difference in P-gp between nonhuman primates and humans. However, human and cynomolgus monkey P-gp have an amino acid sequence homology of 96%, 35) and a good correlation was observed between in vitro P-gp transport activities of humans and nonhuman primates. 36, 37) Therefore, another possibility may exist, in which metoclopramide penetration across the monkey BBB involves an influx transporter(s) in addition to P-gp-mediated active efflux because of influx transporter expression for relatively lipophilic cationic drugs, as suggested previously. 38, 39) With regard to non-P-gp substrates, the K p,uu,ISF value of antipyrine, Concentrations of 12 compounds in plasma (C plasma ), ISF (C ISF ), and CSF (C CSF ) were determined at 3 (propranolol and lamotrigine) or 4 h after a constant intravenous infusion with an intravenous bolus dose in cynomolgus monkeys. Priming doses and infusion rates are given under Materials and Methods. Plasma unbound concentrations (C u,plasma ) were obtained from the product of C plasma and unbound fractions in cynomolgus monkey plasma (f u,plasma ). K p,uu,CSF and K p,uu,ISF represent C CSF -to-C u,plasma and C ISF -to-C u,plasma ratios, respectively. K p,uu,CSF/ISF represents the ratio of the mean of C CSF to that of C ISF , and other data represent the mean « SEM of three to five animals.
a
The concentrations and parameters were determined at 3 h because C ISF was obtained from only two animals due to malfunction of a fraction collector at 4 h. *Significantly lower than unity (p < 0.05). The relationship between the in vitro human P-gp corrected efflux ratio (CER) and the K p,uu,ISF (A), K p,uu,CSF (B), or K p,uu,brain (C) in cynomolgus monkeys. The K p,uu,ISF or K p,uu,CSF is shown as the mean « SEM of three to five animals, and the K p,uu,brain is presented as the value from one animal. The CER is shown as the mean (n = 4). 1, antipyrine; 2, carbamazepine; 3, midazolam; 4, lamotrigine; 5, propranolol; 6, metoclopramide; 7, ondansetron; 8, E2074; 9, risperidone; 10, verapamil; 11, desloratadine; 12, quinidine. Data are taken from Tables 1 and 3, and Supplementary Table 3 . carbamazepine, lamotrigine, and propranolol was close to unity, whereas that of midazolam was somewhat lower than that of other non-P-gp substrates ( Table 3) . In vitro transport studies confirmed that midazolam is not a substrate of P-gp (present study) or BCRP, 17) which is consistent with a previous in vivo study, where midazolam showed no increase in K p,brain in mdr1a/1b (-/-) mice. 34) Hence, midazolam may undergo active efflux by BBB transporters distinct from P-gp and BCRP in cynomolgus monkeys.
P-gp was detected in the cynomolgus monkey choroid plexus (BCSFB) as well as the brain capillary-enriched fraction (BBB) (Supplemental Fig. 1) , which was consistent with the findings of a previous rodent study, 18) where P-gp was reported to be localized to the cytoplasm or subapical region of the choroid plexus epithelial cells. The cellular localization of P-gp in the choroid plexus suggested that P-gp does not limit drug penetration into the CSF at the BCSFB. Previous reports demonstrated that a defect of P-gp caused a significant increase in the C CSF as well as C brain and C u,brain . 17, 34) These findings suggest that diffusion across the ependymal layer followed by active efflux at the BBB significantly contributes to the C CSF in rodents. This would hold true for nonhuman primates because the K p,uu,CSF of most P-gp substrates was significantly below unity (Table 3) , and compounds with higher in vitro P-gp CERs showed lower K p,uu,CSF in cynomolgus monkeys (Fig. 2B) , as reported previously in rhesus monkeys. 37) Consistent with the findings in previous rodent studies, 14, 16, 17) the K p,uu,CSF in cynomolgus monkeys showed a trend of slightly overestimating the K p,uu,ISF for good P-gp substrates except for risperidone (Table 3) ; however, this overestimation was within a factor of two for weak P-gp substrates, and within a factor of three even for good P-gp substrates ( Table 3 and Fig. 3A) . Thus, the impact of active efflux by P-gp at the BBB on the magnitude of the differences between K p,uu,ISF and K p,uu,CSF was less pronounced in nonhuman primates than in rodents.
17) The K p,uu,CSF of the non-P-gp substrates antipyrine, carbamazepine, midazolam, and lamotrigine approximated the K p,uu,ISF , and the K p,uu,CSF of propranolol was approximately 2-fold below the K p,uu,ISF ( Table 3) . These results suggest that unless a test compound is a good P-gp substrate, the C CSF can be used to approximate the C ISF in nonhuman primates and can help compound prioritization for further drug development. Moreover, even if a compound is a good P-gp substrate with transport activity equivalent to desloratadine and quinidine, overestimation of the C ISF by C CSF could be within 3-fold. Therefore, C CSF could be used as a surrogate for C ISF in nonhuman primates for both P-gp and non-Pgp substrates with high membrane permeability. However, special consideration should be given when drugs act as substrates of organic anion transporting polypeptides and organic anion transporter 3 (OAT3), which actively remove their substrates from the CSF at the BCSFB. [40] [41] [42] In fact, the C CSF of benzylpenicillin (an OAT3 substrate) was far below the C u,brain in rats. 17) Because the product of the C brain and f u,brain has also been used as an alternative estimate of C ISF in CNS drug discovery, 14, 43) this approach was applied to nonhuman primates (Supplemental Table 3 ). However, the correlation between K p,uu,brain , estimated by drug binding to brain homogenate, and K p,uu,ISF was poor, and the K p,uu,brain showed a trend of overestimating the K p,uu,ISF for propranolol, E2074, desloratadine, and risperidone, which are outliers by a factor of three (Fig. 3B) . It is generally accepted that the brain homogenate method can be used to evaluate nonspecific binding of drugs to proteins and lipids in brain tissues. The intracellular pH gradient is a possible factor causing overestimation of f u,brain because basic drugs can become trapped in intracellular compartments, such as lysosomes. Fridén et al. demonstrated that the brain homogenate method showed higher f u,brain values for basic compounds compared with the brain slice method, and f u,brain from brain homogenate with consideration of pH partitioning across the cell membrane and membranes of intracellular lysosomes accounts for the intrabrain distribution of basic compounds. 44) This may hold true for the present nonhuman primate study because all test compounds for which the K p,uu,brain were at least 3-fold greater than the K p,uu,ISF were basic ( Table 1) . Except for lipophilic basic compounds, the C u,brain likely approximates the C ISF , even in nonhuman primates, but further studies will be required.
In conclusion, this study simultaneously examined C CSF and C ISF in cynomolgus monkeys by intracerebral microdialysis in conjunction with cisternal CSF sampling, and the K p,uu,ISF and K p,uu,CSF of typical P-gp substrates were much lower than unity, demonstrating the dominant role of P-gp in limiting CNS distribution of the substrates in nonhuman primates. Although the C CSF of typical P-gp substrates showed a trend of slightly overestimating C ISF , the differences were less than 3-fold for all tested compounds, suggesting that C CSF could be used as a surrogate for C ISF in nonhuman primates. The findings of this study provide further insight into the distribution of drugs in the CNS, including P-gp substrates, in nonhuman primates, and contribute to existing knowledge of CNS drug discovery.
